DRESDEN, Germany, August. 11, 2021 /BioInformant/ — denovoMATRIX GmbH, a leading developer of technologies which enable high quality stem cell expansion, today announced the publication of patent application US2021/0145980, titled ‘non-covalently assembled matrix layer’. The patent is expected to provide broad protection for denovoMATRIX’ proprietary screenMATRIX and myMATRIX product lines in the Unites States. [Read more…]
EV Biologics Signs LOI with Lonza Cell & Gene Therapy
NASHVILLE, TN, July 22, 2021 — EV Biologics (OTC PINK:YECO) announced that it has signed a Letter of Intent (LOI) with Lonza Cell & Gene Therapy for Process Development and Gap Analysis for biomanufacturing of a novel therapeutic composition, comprising extracellular vesicles (EVs) and particles, as well as other secreted factors derived from selected stem/progenitor cells, such as mesenchymal stromal cells (MSCs). [Read more…]
Organicell™ Announces FDA Approval Of IND Application For The Use Of Zofin™ In COVID-19 Long Haulers
Miami, FL (July 21, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, for the treatment of ‘Prolonged COVID-19 Symptoms’ (“Long Haulers”). [Read more…]
Charles River Snags Gene Therapy CDMO Vigene Biosciences for $292.5M
June 29, 2021, Wilmington, MA — Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Vigene Biosciences, Inc. for $292.5 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes additional payments of up to $57.5 million, contingent on future performance. [Read more…]
